Regulations and Guidelines for Toxic Exposures in the Workplace

2012 ◽  
pp. 5-28
Author(s):  
Celeste Monforton
Keyword(s):  
Toxic Exposures ◽  
Regulations And Guidelines

A Critical Appraisal of Assessment and Evaluation Reforms At Datta Meghe Institute of Medical Sciences (Deemed to be University) From 2006 Till 2017: A Study Protocol (Preprint)

2020 ◽  
Author(s):  
Dr. Priyanka Jaiswal ◽  
Dr. Ved Prakash Mishra ◽  
Dr. Minal Chaudhary ◽  
Dr. Sunita Vagha ◽  
Dr. Sachin Damke ◽  
...  
Keyword(s):  
Study Protocol ◽  
Critical Appraisal ◽  
Evaluation Process ◽  
Outcome Analysis ◽  
Medical Sciences ◽  
User Friendliness ◽  
Assessment And Evaluation ◽  
Need Analysis ◽  
The University ◽  
Regulations And Guidelines

UNSTRUCTURED DattaMeghe Institute of Medical Sciences has been declared as Deemed to be University [DMIMS (DU)] under section 3 of UGC Act, 1996 in the year 2005. The University examinations are conducted as per the rules, regulations and guidelines issued by the various Apical councils of India from time to time. The first University exam was conducted in the year 2006. DMIMS (DU) has initiated various reforms by its own in assessment and evaluation process based on needs. For any system to thrive, it needs to be constantly upgraded and critically evaluated. Therefore, a study is undertaken with this in mind and thereby aimed at evaluation and validation of the assessment and evaluation reforms formulated and implemented at DMIMS (DU) since its inception (year 2006).Need analysis for the assessment and evaluation reforms will be carried out on the basis of feedbacks and reports received from respective stakeholders (Students, Faculty and External examiners) from time to time. Outcome analysis of the Feedbacks and reports will be done subsequently after the implementation of the assessment and evaluation reforms. Further based on the outcome analysis, reforms will be validated into following parameters: Objectivity, Responsiveness, User friendliness, Residual component (not covered in above 3 parameters)and a satisfactory index will be derived. If satisfactory index for reform is 100%, it will be concluded that reforms are well received and good to excellent in nature. Total 33 assessment and evaluation reforms have beenimplemented since year 2006. These reforms will be categorised into Pre-Examination (n=18), On Site Examination (n=05) and Post Examination (n=10), and in each category, they will befurther classified into academic (Total =15) and administrative (Total = 18) on the basis of their domain for the ease of structuring and implementation.All the 33 reforms will be validated on the basis of defined parameters. They will be found satisfactory.

scholarly journals Systematic Review of Human Poisoning and Toxic Exposures in Myanmar

2021 ◽  
Vol 18 (7) ◽  
pp. 3576
Author(s):  
Meghan A. Cook ◽  
Pardeep S. Jagpal ◽  
Khin Hnin Pwint ◽  
Lai Lai San ◽  
Saint Saint Kyaw Thein ◽  
...  
Keyword(s):  
Public Health ◽  
Systematic Review ◽  
Drugs Of Abuse ◽  
International Health ◽  
Petroleum Products ◽  
Treatment Unit ◽  
Middle Income ◽  
Public Health Burden ◽  
Toxic Exposures ◽  
Human Poisoning

The International Health Regulations (2005) promote national capacity in core institutions so that countries can better detect, respond to and recover from public health emergencies. In accordance with the ‘all hazards’ approach to public health risk, this systematic review examines poisoning and toxic exposures in Myanmar. A systematic literature search was undertaken to find articles pertaining to poisoning in Myanmar published between 1998 and 2020. A number of poisoning risks are identified in this review, including snakebites, heavy metals, drugs of abuse, agrochemicals and traditional medicine. Patterns of poisoning presented in the literature diverge from poisoning priorities reported in other lower-middle income countries in the region. The experience of professionals working in a Yangon-based poison treatment unit also indicate that frequently observed poisoning as a result of pharmaceuticals, methanol, and petroleum products was absent from the literature. Other notable gaps in the available research include assessments of the public health burden of poisoning through self-harm, household exposures to chemicals, paediatric risk and women’s occupational risk of poisoning. There is a limited amount of research available on poisoning outcomes and routes of exposure in Myanmar. Further investigation and research are warranted to provide a more complete assessment of poisoning risk and incidence.

scholarly journals Workplace Toxic Exposures Involving Adolescents Aged 14 to 19 Years

2000 ◽  
Vol 154 (3) ◽  
pp. 234 ◽  
Author(s):  
Alan D. Woolf ◽  
Elizabeth Flynn
Keyword(s):  
Toxic Exposures

Pharmacogenetics: Its Place in Medicine and Biology

1992 ◽  
Vol 5 (6) ◽  
pp. 312-316 ◽  
Author(s):  
Werner Kalow
Keyword(s):  
Infectious Disease ◽  
Drug Toxicity ◽  
Rare Variants ◽  
The Other ◽  
New Drugs ◽  
Case Histories ◽  
High Incidence ◽  
New Knowledge ◽  
Toxic Exposures ◽  
Technical Advances

A young science serves its purpose if it leads not only to new knowledge, but to new insights and concepts. This article opens with examples to illustrate some former thinking that the introduction of pharmacogenetic has overcome. Pharmacogenetic case histories from discovery to the present illustrate the interlocking of observations, technical advances, and changing concepts. There are striking biological similarities between pharmacogenetics and those inborn factors that cause resistance to infectious disease: Both represent person-to-person variations that may help the survival of populations, one when facing massive toxic exposures, the other when facing plagues and epidemics. Thus pharmacogenetics represents a biologically necessary variability of the defenses against chemical intruders, and this includes drugs. While this variability is desirable, drug toxicity occurring on the basis of this variability must be avoided. The most successful defendants against toxicity due to polymorphic (ie, high incidence) variants should be the designers of new drugs. The only defender concerned with rare variants can be the attentive clinician.

Sign in / Sign up

Export Citation Format

Share Document